NCT03336983View on ClinicalTrials.gov

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

December 1, 2017

Primary Completion Date

June 30, 2022

Study Completion Date

April 1, 2023

Conditions

Prostate CancerBone Metastases

Interventions

DRUG

Zoledronic Acid

Prostate cancer patients with hormone sensitive metastatic bone disease will be treated with LHRH-A + Enzalutamide in the presence or absence of Zoledronic Acid

DRUG

Enzalutamide

Patients from both arms will be treated with LHRH-A + Enzalutamide

Trial Locations (1)

25123

Azienda Ospedaliera Spedali Civili di Brescia, Brescia

All Listed Sponsors

lead

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

OTHER

NCT03336983 - Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients | Biotech Hunter | Biotech Hunter